Table I.

Association between the expression of miR-28-5p with clinicopathological features in patients with gastric cancer.

Parameter	n	miR-28-5p folda	P-valueb
Age, years
<65	59	0.77 (0.29–1.57)	0.536
≥65	32	0.65 (0.30–1.11)
Gender
Male	69	0.82 (0.34–1.52)	0.082
Female	22	0.40 (0.28–0.79)
Location
Upper third	4	0.23 (0.11–0.38)	0.131
Middle third	12	0.62 (0.26–1.01)
Lower third	63	0.74 (0.31–1.54)
Extensive	12	1.00 (0.42–2.47)
Gross type
Localized	11	0.37 (0.10–1.54)	0.247
Infiltrative	80	0.76 (0.31–1.47)
Size (max. diameter), cm
<5	42	0.76 (0.41–1.65)	0.324
≥5	49	0.67 (0.23–1.40)
Histological type
Intestinal	48	0.64 (0.26–1.08)	0.120
Diffuse	43	0.84 (0.39–1.95)
Depth of invasion (pT)
T1, T2, T3	59	0.81 (0.39–1.95)	0.024
T4	32	0.50 (0.22–0.94)
Lymph node status (pN)
N0, N1, N2	62	0.79 (0.37–1.71)	0.035
N3	29	0.56 (0.19–0.99)
Lymph node metastasis
No	24	0.95 (0.43–2.06)	0.222
Yes	67	0.71 (0.27–1.12)
Lymphatic invasion
No	72	0.76 (0.31–1.47)	0.667
Yes	19	0.71 (0.20–1.88)
AJCCTNM stage
I, II, IIIa, IIIb	79	0.79 (0.33–1.57)	0.030
IIIc, IV	12	0.44 (0.18–0.80)

^aMedian of relative expression, with 25–75th percentile in parenthesis.

^bMann-Whitney test (for two groups) or Kruskal Wallis test (for >2 groups). miR-28-5p, microRNA-28-5p; AJCC, American Joint Committee on Cancer; TNM, tumor node metastasis.